	US 11,952,423 B2
	Bispecific antibody
Hiroshi Shiku, Tsu (JP); Yasushi Akahori, Tsu (JP); Kento Tanaka, Tokyo (JP); Ayaka Yatsu, Tokyo (JP); Junya Ichikawa, Tokyo (JP); Toshiaki Ohtsuka, Tokyo (JP); Shiho Kozuma, Tokyo (JP); Ryuji Hashimoto, Tokyo (JP); Makiko Nakayama, Tokyo (JP); Naoya Shinozaki, Tokyo (JP); Kensuke Nakamura, Tokyo (JP); Ichiro Watanabe, Tokyo (JP); and Shinji Furuzono, Tokyo (JP)
Assigned to MIE UNIVERSITY, Tsu (JP); and DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
Filed by MIE UNIVERSITY, Tsu (JP); and DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
Filed on May 16, 2023, as Appl. No. 18/318,610.
Application 18/318,610 is a continuation of application No. 17/799,648, previously published as PCT/JP2021/013378, filed on Mar. 29, 2021.
Claims priority of application No. 2020-061476 (JP), filed on Mar. 30, 2020.
Prior Publication US 2023/0287121 A1, Sep. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/32 (2006.01)

CPC C07K 16/2809 (2013.01) [C07K 16/32 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)]

28 Claims

1. An antibody that binds specifically to human HLA/NY-ESO or a binding fragment thereof comprising:

(i) a heavy chain CDRH1 consisting of the amino acid sequence as shown in SEQ ID NO: 54,

(ii) a heavy chain CDRH2 consisting of the amino acid sequence as shown in SEQ ID NO: 55,

(iii) a heavy chain CDRH3 consisting of the amino acid sequence as shown in SEQ ID NO: 56,

(iv) a light chain CDRL1 consisting of an amino acid sequence derived from the amino acid sequence as shown in SEQ ID NO: 57 in which amino acid 7 is W,

(v) a light chain CDRL2 consisting of the amino acid sequence of DNN, and

(vi) a light chain CDRL3 consisting of the amino acid sequence as shown in SEQ ID NO: 59.